Last reviewed · How we verify
NCT03653936: KY
Neuro-ocular Baselines in a Sports Setting
trial testing HITT device in Wave Form Signals Coming From the Eye in a Healthy Cohort in 63 participants. Completed in 30 November 2018.
30 November 2018
Quick facts
| Lead sponsor | Rebiscan, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 1 April 2018 |
| Primary completion | 30 November 2018 |
| Estimated completion | 30 November 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HITT device
Conditions studied
- Wave Form Signals Coming From the Eye in a Healthy Cohort — all drugs for Wave Form Signals Coming From the Eye in a Healthy Cohort →
Sponsor
Rebiscan, Inc.
Who can join
Adults 11 to 21, any sex, with Wave Form Signals Coming From the Eye in a Healthy Cohort. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rebion (Rebiscan, Inc) has developed a noninvasive, handheld device that uses retinal birefringence scanning (RBS) to rapidly assess eye fixation and retinal integrity in adults and children. The proprietary technology uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. The project described herein aims to provide accurate assessment of brain dysfunction in TBI (Traumatic Brain Injury) patients through the use of the developed device, which is called the Head and Intraocular Trauma Test (HITT) device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03653936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HITT device
Trials testing the same drug.
- NCT03249818 — HITT Device Pilot Testing for Traumatic Brain Injury · NA · completed
Other Rebiscan, Inc. trials
Trials by the same sponsor.
- NCT06142435 — mTBI Identification and Monitoring Through Retinal Scanning · recruiting
- NCT05092295 — Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury · active not recruiting
- NCT05092282 — HITT for the Identification of Mild Traumatic Brain Injury · active not recruiting
- NCT03919708 — Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging · withdrawn
- NCT03249818 — HITT Device Pilot Testing for Traumatic Brain Injury · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03653936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rebiscan, Inc.
- Last refreshed: 18 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing